Quantification of cinacalcet by LC-MS/MS using liquid-liquid extraction from 50μL of plasma

Journal of Pharmaceutical and Biomedical Analysis

Volumn 56, Issue 2, 2011, Pages 373-381

  Nirogi, Ramakrishna ^a   Kandikere, Vishwottam ^a   Komarneni, Prashanth ^a   Aleti, Raghupathi ^a   Padala, NagaSuryaPrakash ^a   Kalaikadiban, Ilayaraja ^a  

^a SUVEN LIFE SCIENCES LTD   (India)

Author keywords

Cinacalcet; Clinical trials; Liquid chromatography tandem mass spectrometry; Plasma

Indexed keywords

CINACALCET; FLUOXETINE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG HALF LIFE; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIMIT OF QUANTITATION; LIQUID LIQUID EXTRACTION; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY;

ADMINISTRATION, ORAL; ANIMALS; CALCIMIMETIC AGENTS; CALIBRATION; CHEMICAL FRACTIONATION; CHROMATOGRAPHY, LIQUID; CHROMATOGRAPHY, REVERSE-PHASE; ETHER, ETHYL; METHYLENE CHLORIDE; MODELS, BIOLOGICAL; NAPHTHALENES; RATS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SOLVENTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 79960056566     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.05.032     Document Type: Article

References (9)

1. Padhi D., Harris R. Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin. Pharmacokinet. 2009, 48:303-311.
2. Nemeth E.F., Heaton W.H., Miller M., Fox J., Balandrin M.F., Van Wagenen B.C., Colloton M., Karbon W., Scherrer J., Shatzen E., Rishton G., Scully S., Qi M., Harris R., Lacey D., Martin D. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J. Pharmacol. Exp. Ther. 2004, 308:627-635.
3. Padhi D., Salfi M., Harris R.Z. The pharmacokinetics of cinacalcet are unaffected following consumption of high- and low-fat meals. Am. J. Ther. 2007, 14:235-240.
4. Kumar G.N., Sproul C., Poppe L., Turner S., Gohdes M., Ghoborah H., Padhi D., Roskos L. Metabolism and disposition of calcimimetic agent cinacalcet HCl in humans and animal models. Drug Metab. Dispos. 2004, 32:1491-1500.
5. Harris R.Z., Padhi D., Marbury T.C., Noveck R.J., Salfi M., Sullivan J.T. Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 2000mg once daily. Am. J. Kidney Dis. 2004, 44:1070-1076.
6. Padhi D., Harris R.Z., Salfi M., Sullivan J.T. No effect of renal function or dialysis on pharmacokinetics of cinacalcet (Sensipar/Mimpara). Clin. Pharmacokinet. 2005, 44:509-516.
7. Ohashi N., Uematsu T., Nagashima S., Kanamaru M., Togawa A., Hishida A., Uchida E., Akizawa T., Koshikawa S. The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis. Br. J. Clin. Pharmacol. 2004, 57:726-734.
8. Nakashima D., Takama H., Ogasawara Y., Kawakami T., Nishitoba T., Hoshi S., Uchida E., Tanaka H. Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies. J. Clin. Pharmacol. 2007, 47:1311-1319.
9. Padhi D., Harris R.Z., Salfi M., Noveck R.J., Sullivan J.T. Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment: phase I, open-label, parallel-group, single dose, single-centre study. Clin. Drug Invest. 2008, 28:635-643.